Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell…
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease…
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New detailed data from the RELIEVE…
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval…
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris,…
Availability of the revised financial statements for Sanofi excluding Opella Paris, France – December 6, 2024. Following the press release…
